2 professor of internal medicine,Endocrinology and metabolism research center ,shiraz university of medical sciences.

3 Assistant professor of surgery,surgery dep,namazi hospital,shiraz university of medical sciences.


Objectives: To determine the epidemiological aspect of mucormycosis, the nature of malignancies complicated by mucormycosis, the initial site of involvement and the subsequent outcome.Methods: This was a cross-sectional study which was performed by reviewing the medical records of 95 patients with leukemia complicated with biopsy-proven mucormycosis admitted to the educational hospitals affiliated with Shiraz University of Medical Sciences over a 21-year period. We recorded demographic information including age and sex and disease characteristics such as type of leukemia, site of involvement, paraclinical findings at the time of admission and the outcome of the patients. The incidence of mucormycosis in leukemia was determined by identifying the number of leukemia patients diagnosed within the last 17 years.Results: The male to female ratio was 2.39:1 in of 95 patients studied. The overall incidence rate of mucormycosis was 4.27 per 100 leukemic patients in last 17 years which showed a decreasing trend from 2001 to 2011. The most frequent type of leukemia was acute myelogenous leukemia (AML) which was found in 58 patients (61.5%). The most common site of initial tumor involvement was sinonasal (90.16%). The mortality rate was about 54%, compared to the mortality rate of about 43.24% in patients with best prognosis of AML.Conclusion: The incidence of mucormycosis in leukemia showed a decreasing trend in our country and its recent incidence is comparable to that of other regions. The best preventive method against this lethal infection is to modify and control the environment which reduces the risk of exposure to air-born fungal spores.


  1. Lerchenmüller C, Göner M, Büchner T, Berdel WE. Rhinocerebralzygomycosis in a patient with acute lymphoblastic leukemia. Ann Oncol 2001;12(3):415-9.
  2. Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al. Mucormycosis in hematologic patients. Haematologica 2004;89(2):207-14.
  3. Barr A, Nolan M, Grant W, Costello C, Petrou MA. Rhinoorbital and pulmonary zygomycosis post pulmonary aspergilloma in a patient with chronic lymphocytic leukaemia. Acta Biomed 2006;77 Suppl 4:13-8.
  4. Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 2000;85(10):1068-71.
  5. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10Suppl 1:31-47.
  6. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer centre. Clin Infect Dis 2000;30(6):851-6.
  7. Siwek GT, Dodgson KJ, de Magalhaes- Silverman M, Bartelt LA, Kilborn SB, Hoth PL, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004;39(4):584-7.
  8. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350(9):950-2.
  9. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39(5):743-6.
  10. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009;15(9):1395-401.
  11. Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, Thulkar S. Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol 2000;17(2):111-6.
  12. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection- related mortality in the U.S. Diabetes Care 2001;24(6):1044-9.
  13. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5):634-53.
  14. Martin-Moro JG, Calleja JM, Garcia MB, Carretero JL, Rodriguez JG. Rhinoorbitocerebral mucormycosis: a case report and literature review. Med Oral Patol Oral Cir Bucal 2008;13(12):E792-5.
  15. Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect 2009;15 Suppl 5:10-4.
  16. Chakrabrati A, Das A, Sharma A, Panda N, Das S, Gupta KL, et al. Ten years’ experience in zygomycosis at a tertiary care center in India. Journal of Infection 2001;42(4):261-6.
  17. Grant JM, St-Germain G, McDonald JC. Successful treatment of invasive Rhizopus infection in a child with thalassemia. Med Mycol 2006;44(8):771-5.
  18. Sharma R, Shivanand G, Kumar R, Prem S, Kandpal H, Das CJ, et al. Isolated renal mucormycosis: An unusual cause of acute renal infarction in a boy with aplastic anaemia. Br J Radiol 2006;79(943):e19-21.
  19. Gadadhar H, Hawkins S, Huffstutter JE, Panda M. Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy. J Clin Rheumatol 2007;13(6):361-2.
  20. Devlin SM, Hu B, Ippoliti A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci 2007;52(9):2078-81.
  21. Ferguson AD. Rhinocerebral mucormycosis acquired after a short course of prednisone therapy. J Am Osteopath Assoc 2007;107(11):491-3.
  22. Jung SH, Kim SW, Park CS, Song CE, Cho JH, Lee JH, et al. Rhinocerebral Mucormycosis: consideration of prognostic factors and treatment modality. Auris Nasus Larynx 2009;36(3):274-9.